Article Details

Roivant Sciences Strikes SPAC Deal Valuing The Drug Company At $7.3 Billion

Retrieved on: 2021-05-03 11:03:45

Tags for this article:

Click the tags to see associated articles and topics

Roivant Sciences Strikes SPAC Deal Valuing The Drug Company At $7.3 Billion. View article details on hiswai:

Excerpt

... a private financing, in which Palantir Technologies, Viking Global Investors, Softbank and others will invest $200 million in the publicly traded equity.

Article found on: www.forbes.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up